ALVAL.PA - Valbiotis SA

Financial Statements(Q) of Valbiotis SA(ALVAL.PA), Valbiotis SA engages in the research and development of health nutrition products to prevent and com

Valbiotis SA

ALVAL.PA

EURONEXT

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

3.87 EUR

-0.02 (-0.517%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

All Income Statement Balance Sheet Statement Cash Flow Statement Retained Earning Schedule PPE Schedule Intangible and Goodwill Schedule

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.